Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL12 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL12 (SDF-1 alpha) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli expressed. |
View CXCL12 Products |
| Gene Delivery | CXCL12 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CXCL12 Products |
| Benchmark Ab | Anti-CXCL12 neutralizing antibody Recombinant positive control sequence based on clinical benchmarks. |
View CXCL12 Products |
| Validator | CXCL12 siRNA Set For knockdown verification. |
View CXCL12 Products |
| Related Target A | CXCR4 Primary receptor mediating CXCL12-induced chemotaxis and tumor microenvironment homing. |
View CXCR4 Products |
| Related Target B | ACKR3 Alternative scavenger receptor (CXCR7) regulating CXCL12 gradients and non-canonical signaling. |
View ACKR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform-specific targeting (SDF-1 alpha vs beta) | Sequence-verified, highly pure recombinant CXCL12 (SDF-1 alpha) with mass spec verification. |
| Receptor selectivity (CXCR4 vs ACKR3) | Cross-screening panel featuring high-purity CXCR4 and ACKR3 reagents. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CXCL12 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCL12 therapeutics is intensifying, with major players shifting focus from traditional mAbs to specialized modalities like Spiegelmers (L-RNA aptamers) and bispecific constructs designed to disrupt the tumor microenvironment. As first-generation therapies reach the clinic, the next wave of R&D is targeting combination regimens to overcome immune exclusion in "cold" tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Aptamers (Spiegelmer) | TME Pharma (NOX-A12) | Glioblastoma, Pancreatic Cancer | High-affinity binding kinetics (Need sequence-verified CXCL12) |
| Monoclonal Antibodies | Academic / Biotech Consortia | Hematological Malignancies, Metastasis | Neutralization assays (Need endotoxin-controlled CXCL12) |
| Small Molecules / Peptides | Sanofi, Pfizer, Polyphor (targeting CXCR4/CXCL12 axis) | Stem Cell Mobilization, Solid Tumors | Receptor competition assays (Need Lentivirus for CXCR4 stable cell lines) |